

# Breakthrough Therapy (BT) Designation-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BEE6CB0BC06MEN.html>

Date: May 2018

Pages: 137

Price: US\$ 3,480.00 (Single User License)

ID: BEE6CB0BC06MEN

## Abstracts

### Report Summary

Breakthrough Therapy (BT) Designation-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Breakthrough Therapy (BT) Designation industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Breakthrough Therapy (BT) Designation 2013-2017, and development forecast 2018-2023

Main market players of Breakthrough Therapy (BT) Designation in EMEA, with company and product introduction, position in the Breakthrough Therapy (BT) Designation market  
Market status and development trend of Breakthrough Therapy (BT) Designation by types and applications

Cost and profit status of Breakthrough Therapy (BT) Designation, and marketing status  
Market growth drivers and challenges

The report segments the EMEA Breakthrough Therapy (BT) Designation market as:

EMEA Breakthrough Therapy (BT) Designation Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

## Africa

EMEA Breakthrough Therapy (BT) Designation Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oncology  
Infectious Diseases  
Rare Diseases  
Autoimmune Diseases  
Pulmonary Diseases  
Neurological Disorders  
Others

EMEA Breakthrough Therapy (BT) Designation Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Clinic  
Research Institute  
Laboratories

EMEA Breakthrough Therapy (BT) Designation Market: Players Segment Analysis (Company and Product introduction, Breakthrough Therapy (BT) Designation Sales Volume, Revenue, Price and Gross Margin):

Roche  
Abbvie  
Novartis International AG  
Janssen  
BMS  
Eli Lilly  
Gilead  
Sanofi  
Regeneron  
Acadia  
Boehringer Ingelheim  
Amgen  
AstraZeneca

GlaxoSmithKline  
Vertex  
Alexion  
Merck  
Jazz Pharmaceuticals  
Exelixis  
Eisai  
Takeda  
Pfizer

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF BREAKTHROUGH THERAPY (BT) DESIGNATION**

- 1.1 Definition of Breakthrough Therapy (BT) Designation in This Report
- 1.2 Commercial Types of Breakthrough Therapy (BT) Designation
  - 1.2.1 Oncology
  - 1.2.2 Infectious Diseases
  - 1.2.3 Rare Diseases
  - 1.2.4 Autoimmune Diseases
  - 1.2.5 Pulmonary Diseases
  - 1.2.6 Neurological Disorders
  - 1.2.7 Others
- 1.3 Downstream Application of Breakthrough Therapy (BT) Designation
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Research Institute
  - 1.3.4 Laboratories
- 1.4 Development History of Breakthrough Therapy (BT) Designation
- 1.5 Market Status and Trend of Breakthrough Therapy (BT) Designation 2013-2023
  - 1.5.1 Asia Pacific Breakthrough Therapy (BT) Designation Market Status and Trend 2013-2023
  - 1.5.2 Regional Breakthrough Therapy (BT) Designation Market Status and Trend 2013-2023

### **CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Breakthrough Therapy (BT) Designation in Asia Pacific 2013-2017
- 2.2 Consumption Market of Breakthrough Therapy (BT) Designation in Asia Pacific by Regions
  - 2.2.1 Consumption Volume of Breakthrough Therapy (BT) Designation in Asia Pacific by Regions
  - 2.2.2 Revenue of Breakthrough Therapy (BT) Designation in Asia Pacific by Regions
- 2.3 Market Analysis of Breakthrough Therapy (BT) Designation in Asia Pacific by Regions
  - 2.3.1 Market Analysis of Breakthrough Therapy (BT) Designation in China 2013-2017
  - 2.3.2 Market Analysis of Breakthrough Therapy (BT) Designation in Japan 2013-2017
  - 2.3.3 Market Analysis of Breakthrough Therapy (BT) Designation in Korea 2013-2017
  - 2.3.4 Market Analysis of Breakthrough Therapy (BT) Designation in India 2013-2017

2.3.5 Market Analysis of Breakthrough Therapy (BT) Designation in Southeast Asia 2013-2017

2.3.6 Market Analysis of Breakthrough Therapy (BT) Designation in Australia 2013-2017

2.4 Market Development Forecast of Breakthrough Therapy (BT) Designation in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of Breakthrough Therapy (BT) Designation in Asia Pacific 2018-2023

2.4.2 Market Development Forecast of Breakthrough Therapy (BT) Designation by Regions 2018-2023

## **CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Breakthrough Therapy (BT) Designation in Asia Pacific by Types

3.1.2 Revenue of Breakthrough Therapy (BT) Designation in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Breakthrough Therapy (BT) Designation in Asia Pacific by Types

## **CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Breakthrough Therapy (BT) Designation in Asia Pacific by Downstream Industry

4.2 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Major Countries

4.2.1 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in China

4.2.2 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Japan

4.2.3 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Korea

4.2.4 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in India

4.2.5 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Australia

4.3 Market Forecast of Breakthrough Therapy (BT) Designation in Asia Pacific by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION**

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 Breakthrough Therapy (BT) Designation Downstream Industry Situation and Trend Overview

## **CHAPTER 6 BREAKTHROUGH THERAPY (BT) DESIGNATION MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC**

6.1 Sales Volume of Breakthrough Therapy (BT) Designation in Asia Pacific by Major Players

6.2 Revenue of Breakthrough Therapy (BT) Designation in Asia Pacific by Major Players

6.3 Basic Information of Breakthrough Therapy (BT) Designation by Major Players

6.3.1 Headquarters Location and Established Time of Breakthrough Therapy (BT) Designation Major Players

6.3.2 Employees and Revenue Level of Breakthrough Therapy (BT) Designation Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 BREAKTHROUGH THERAPY (BT) DESIGNATION MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Roche

7.1.1 Company profile

7.1.2 Representative Breakthrough Therapy (BT) Designation Product

7.1.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Roche

7.2 Abbvie

7.2.1 Company profile

7.2.2 Representative Breakthrough Therapy (BT) Designation Product

7.2.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Abbvie

7.3 Novartis International AG

7.3.1 Company profile

7.3.2 Representative Breakthrough Therapy (BT) Designation Product

7.3.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Novartis International AG

7.4 Janssen

7.4.1 Company profile

7.4.2 Representative Breakthrough Therapy (BT) Designation Product

7.4.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Janssen

7.5 BMS

7.5.1 Company profile

7.5.2 Representative Breakthrough Therapy (BT) Designation Product

7.5.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of BMS

7.6 Eli Lilly

7.6.1 Company profile

7.6.2 Representative Breakthrough Therapy (BT) Designation Product

7.6.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Eli Lilly

7.7 Gilead

7.7.1 Company profile

7.7.2 Representative Breakthrough Therapy (BT) Designation Product

7.7.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Gilead

7.8 Sanofi

7.8.1 Company profile

7.8.2 Representative Breakthrough Therapy (BT) Designation Product

7.8.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Sanofi

7.9 Regeneron

7.9.1 Company profile

- 7.9.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.9.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Regeneron
- 7.10 Acadia
  - 7.10.1 Company profile
  - 7.10.2 Representative Breakthrough Therapy (BT) Designation Product
  - 7.10.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Acadia
- 7.11 Boehringer Ingelheim
  - 7.11.1 Company profile
  - 7.11.2 Representative Breakthrough Therapy (BT) Designation Product
  - 7.11.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.12 Amgen
  - 7.12.1 Company profile
  - 7.12.2 Representative Breakthrough Therapy (BT) Designation Product
  - 7.12.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Amgen
- 7.13 AstraZeneca
  - 7.13.1 Company profile
  - 7.13.2 Representative Breakthrough Therapy (BT) Designation Product
  - 7.13.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.14 GlaxoSmithKline
  - 7.14.1 Company profile
  - 7.14.2 Representative Breakthrough Therapy (BT) Designation Product
  - 7.14.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.15 Vertex
  - 7.15.1 Company profile
  - 7.15.2 Representative Breakthrough Therapy (BT) Designation Product
  - 7.15.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Vertex
- 7.16 Alexion
- 7.17 Merck
- 7.18 Jazz Pharmaceuticals
- 7.19 Exelixis
- 7.20 Eisai
- 7.21 Takeda



7.22 Pfizer

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION**

8.1 Industry Chain of Breakthrough Therapy (BT) Designation

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION**

9.1 Cost Structure Analysis of Breakthrough Therapy (BT) Designation

9.2 Raw Materials Cost Analysis of Breakthrough Therapy (BT) Designation

9.3 Labor Cost Analysis of Breakthrough Therapy (BT) Designation

9.4 Manufacturing Expenses Analysis of Breakthrough Therapy (BT) Designation

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Breakthrough Therapy (BT) Designation-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BEE6CB0BC06MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BEE6CB0BC06MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

